{"links":{"feed":"https://www.erudio.com/reports/eter100-nct04523272/feed.json","html":"https://www.erudio.com/reports/eter100-nct04523272","json":"https://www.erudio.com/reports/eter100-nct04523272.json","markdown":"https://www.erudio.com/reports/eter100-nct04523272.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"eter100-nct04523272"}},"request":"https://www.erudio.com/contact?report=eter100-nct04523272"},"offer":{"cited_clinicians":0,"cited_commentary_sources":4,"verified_hcp_statements":44,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":2},"for_sale":false,"one_off_usd":null,"not_for_sale":{"note":"This edition is below our minimum for clinicians and sources, so it is not for sale yet. Contact us if you are still interested. No order can be placed for it; a later edition that reaches the minimum is for sale at its normal price.","contact":"https://www.erudio.com/contact?report=eter100-nct04523272","email":"hello@erudio.com"},"purchase":{"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=eter100-nct04523272","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/eter100-nct04523272","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 44 verified statements · none from confirmed clinicians","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":null,"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-22T22:08:45.246031Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":8,"no_commentary_found":0},"aspects":[{"claim_count":4,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":3,"title":"Primary endpoint: Progression free survival (PFS) evaluated by Independent Review Committee(IRC)"},{"claim_count":1,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes","source_count":1,"title":"Secondary endpoints"},{"claim_count":1,"coverage":"discussed","id":"T3","registry_field":"conditionsModule","source_count":1,"title":"Population and setting"},{"claim_count":7,"coverage":"discussed","id":"T4","registry_field":"armsInterventionsModule.armGroups","source_count":3,"title":"The comparison"},{"claim_count":1,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.interventions","source_count":1,"title":"Safety and tolerability"},{"claim_count":2,"coverage":"discussed","id":"T6","registry_field":"designModule","source_count":1,"title":"Design and conduct"},{"claim_count":4,"coverage":"discussed","id":"A1","source_count":2,"title":"Overall response, complete response and checkpoint-class activity"},{"claim_count":5,"coverage":"discussed","id":"A2","source_count":1,"title":"Cross-trial interpretation and patient-centered selection in advanced kidney cancer"}],"counts":{"beyond_population_findings":1,"beyond_population_statements":5,"cited_clinicians":0,"cited_clinicians_by_role":{},"cited_physicians":0,"cited_sources":6,"claims_by_expression_type":{"comparison":6,"interpretation":12,"opinion":14,"primary_context":5,"restatement":1,"uncertainty":6},"claims_by_kind":{"objective_result":3,"protocol_statement":2,"publication_statement":22,"source_observation":17},"clinician_statements":0,"evidence_units":30,"findings":4,"organisational_accounts":1,"people_cited":2,"people_identity_verified":2,"people_total":3,"screened_sources":24,"verified_claims":44},"findings_index":[{"cited_clinicians":0,"id":"F1","structure":{"claims":8,"claims_by_group":{"comparisons":4,"experience":0,"questions":1,"restated":0,"views":3},"limitations":4,"links":{"context":1,"support":8},"ma_question":true,"named_voices":0,"passages":1,"sources":1,"sources_by_kind":{"media":1}},"title":"ETER100: a speaker likens it to options but avoids PD-L1 with PD-1 access","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-d8365569fa51f2483cb6"],"clause":"avoid PD-L1 with PD-1 access","holders":0},"cited_claim_ids":["claim-363836edbe9b41b8506a","claim-c7ddfc54e0036846b054","claim-e73c8c7a9267ccd7f39b"],"clinicians":false,"holders":0,"speakers":0,"view":"reading"},"evidence_line":"8 statements in 1 source, a podcast or video","holder_line":"No named speaker is counted in this finding: its title's view comes from speakers the source does not name"},{"cited_clinicians":0,"id":"F2","structure":{"claims":11,"claims_by_group":{"comparisons":3,"experience":0,"questions":0,"restated":3,"views":5},"limitations":4,"links":{"context":1,"support":14},"ma_question":true,"named_voices":1,"passages":7,"sources":4,"sources_by_kind":{"commentary":2,"media":1,"publication":1}},"title":"ETER100: what a speaker highlights in the PFS benefit versus Sunitinib","title_holders":{"cited_claim_ids":["claim-12f44659431d71c131fd","claim-150cbb76ecb2cb6fae55","claim-571603ea869453835338"],"clinicians":false,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"11 statements from 1 speaker in 4 sources, 1 of them a podcast or video","holder_line":"The one named speaker in this finding holds this view"},{"cited_clinicians":0,"id":"F3","structure":{"claims":15,"claims_by_group":{"comparisons":0,"experience":0,"questions":4,"restated":3,"views":8},"limitations":4,"links":{"context":5,"support":16},"ma_question":true,"named_voices":1,"passages":13,"sources":3,"sources_by_kind":{"commentary":1,"publication":2}},"title":"ETER100 tolerability: what a speaker relays from the presentation","title_holders":{"cited_claim_ids":["claim-271d426e97b431ace2a0"],"clinicians":false,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"15 statements from 1 speaker in 3 sources","holder_line":"The one named speaker in this finding holds this view"},{"cited_clinicians":0,"id":"F4","population":"beyond","structure":{"claims":5,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":0,"views":4},"limitations":3,"links":{"context":0,"support":5},"ma_question":true,"named_voices":1,"passages":4,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Advanced RCC: how a speaker tailors care with extreme cross-trial caution","title_holders":{"cited_claim_ids":["claim-ff339ef9b7916e2279af","claim-7195bba39bafa637f3a4","claim-2d170aee9261416cc70e"],"clinicians":false,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"5 statements from 1 speaker in 1 source","holder_line":"The one named speaker in this finding holds this view"}],"open_question":{"reason":"No question clinicians left open passed this edition's checks and review.","status":"unavailable"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"One video speaker would avoid PD-L1 inhibition when PD-1 agents are available"},{"id":"section-2","level":2,"title":"One X account sees a “paradigm shift”; one video speaker sees similarity to available combinations"},{"id":"section-3","level":2,"title":"One X account relays a favorable tolerability assessment"},{"id":"section-4","level":2,"title":"Beyond the trial population"},{"id":"section-5","level":3,"title":"One X account emphasizes individualized selection and cautions against cross-trial ranking"},{"id":"section-6","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":4}],"id":"T1","label":"Primary endpoint: Progression free survival (PFS) evaluated by Independent Review Committee(IRC)"},{"findings":[{"id":"F2","shared_claims":1}],"id":"T2","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":1}],"id":"T3","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":5},{"id":"F2","shared_claims":6}],"id":"T4","label":"The comparison"},{"findings":[{"id":"F3","shared_claims":1}],"id":"T5","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":2}],"id":"T6","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-22T22:08:45.246031Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-22T22:22:29Z","record_hash":"f56bf7371b5b5343f76aa8f1e0f6eefc0d61aaf8972fed9dbd479b2cc2b7c007","release_hash":"ea0a93bd4ad84bb661b9e72ce64ba4f876d1bfb42716fb3a87b03adb530e3743","report_id":"erudio-nct04523272","run_id":"24285730-91c4-4b46-8d67-d37307210b07","schema_version":"5.0","slug":"eter100-nct04523272","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"A speaker in the discussion reads ETER100 favorably because its results resemble existing combinations, yet would forgo PD-L1 inhibition if PD-1 agents were available. They speculate that the low complete-response rate could reflect a class-activity difference, without comparative proof. An unverified account separately suggests a change in treatment positioning—a different emphasis, not a documented direct debate. The speaker describes overall survival as immature at the time, not as showing an absence of survival benefit.","examples":[],"meta_description":"24 sources screened · 44 verified statements (0 from clinicians verified by NPI or staff page) from 6 sources · 4 findings. Updated Nov 22, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-22T22:22:29Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":24},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","16 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 25 sources about other trials or topics are not included.","The substantive commentary summarized here comes from three X threads and one video discussion. These sources cannot establish how common a view is among HCPs, and reposts are not additional independent endorsements.","Discussion using unnamed trial references, alternative spellings or other terminology may have been missed. Silence on a topic is not evidence that clinicians have no view.","The video speaker cannot be named, and the video's date is not provided. The November 2021, September 2024 and September 2025 posts must not be interpreted as a sequence showing changing opinion.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","The video and the 2021 selection thread do not name ETER100. The former addresses its regimen and comparator; the latter supplies broader advanced-kidney-cancer treatment-selection context rather than trial-specific results commentary.","The complete-response concern has no numerical rate in the discussion, and the comparisons with other combinations are not head-to-head evidence. The speaker's checkpoint-class explanation remains speculative.","The linked renal publication supplies practical context, not an independently attributed HCP practice survey. Its post-hoc, single-trial analysis may miss subclinical injury, does not resolve long-term renal outcomes, and does not validate routine use of its proposed monitoring schedule.","The primary study population was Chinese and concerned first-line advanced clear-cell RCC; extrapolation beyond that setting requires caution.","No full protocol or exact product labels accompany these sources. Jurisdiction-specific approval, access and prescribing conclusions cannot be drawn."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":2,"registry":0,"regulatory":0,"x_thread":3,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":4,"results":2},"count":6,"evidence_window":{"end":"2025-09-16","start":"2021-11-19"},"retrieval_snapshot":"2026-11-22T21:42:29.826899Z","timeline":[{"count":1,"week":"2021-W46"},{"count":1,"week":"2024-W37"},{"count":1,"week":"2025-W38"}],"undated_sources":3},"quote_policies":[{"id":"clinicaltrials:NCT04523272:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT04523272:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:40907513","quote_policy":"short_quote_link_out"},{"id":"pubmed:42387482","quote_policy":"no_derivatives"},{"id":"openfda:43a4d7f8-48ae-4a63-9108-2fa8e3ea9d9c:20260220","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1461471452985659396:1ec343e7-b7d4-46fd-93f9-3c4ed2384dc4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1461796903654502401:64605a13-37d7-425e-b711-7ddf0b0ddeb1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1835214208599810284:a4894405-9620-41cb-8632-c1b06c186dc1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1835217830398046513:caf415d6-c5a2-49c8-855e-b855c40a6dc8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1835220012207862158:62587608-7a88-44e2-ae58-0029c3c345d0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1835220069338529851:0ff5d82d-0ef7-46e4-9a3e-814fe00b6409","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1835220193254973696:4c66666b-4f80-46be-822b-fca95041b2dc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1835225356007034957:5063ca3c-b799-4d05-951c-9cd34199032b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1835240522929029123:1e3c0cb4-a802-4478-a06e-5ad3dd9f7f2f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1835276425441722425:1a870336-7767-4ce7-8a5c-4d8f03bac2ef","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1835369324627812502:39a322be-cb5a-4616-bfa9-3b2954479ffb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1835371845232554174:a8cc1666-3740-4cc4-8bb2-f222a51696a3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1836777064705220882:b27e8a62-3ea7-4684-99a5-1ac97f4389b1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1837839540335054987:20844714-b21c-417b-b682-6977e18d0405","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1844514889337012289:bb207084-1f0e-413e-82bb-e0091030348f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1963226370667954302:c4991eb9-48d7-46f9-9e4f-a3854ea09bc1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1964289914867970315:66354030-1d96-433f-8cc1-3ce087ec04b0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1964676281091358873:2ce391bb-6f5c-4d02-8222-f9b7291d79be","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1968004706598346971:4e98c2a3-e244-488a-ba5c-ef1f097cb498","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1970217130428657769:717f2e56-9fcc-46ae-9ac7-5efb938bfd71","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2124159676782657770:80e81deb-44fc-43bd-a35d-e547a5682c06","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2124168598457389157:d1e15cc1-1e5e-4c7e-88ba-010ddb92559b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2124170187389685987:e3f3b60d-0370-4d43-ad27-81f37c11dcd9","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:vWHugBwpavE","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":23,"x_video":0,"youtube":1},"by_evidence_role":{"commentary":24},"count":24,"evidence_window":{"end":"2026-11-21","start":"2021-11-18"},"retrieval_snapshot":"2026-11-22T21:42:29.826899Z","timeline":[{"count":2,"week":"2021-W46"},{"count":10,"week":"2024-W37"},{"count":2,"week":"2024-W38"},{"count":1,"week":"2024-W41"},{"count":3,"week":"2025-W36"},{"count":1,"week":"2025-W38"},{"count":1,"week":"2025-W39"},{"count":3,"week":"2026-W47"}],"undated_sources":1},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":27,"registry":0,"regulatory":0,"x_thread":8,"x_video":0,"youtube":9}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"brand_names":{"reason":"No checked-in brand mapping.","status":"unmapped"},"label":"benmelstobart","slug":"benmelstobart"},{"brand_names":{"reason":"No checked-in brand mapping.","status":"unmapped"},"label":"catequentinib","slug":"catequentinib"},{"brand_names":["Sutent"],"label":"sunitinib","slug":"sunitinib"}],"indications":[{"reason":"Unmapped registry condition: Advanced Renal Cancer","status":"unmapped"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Renal cell carcinoma","slug":"renal-cell-carcinoma"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"ETER100","aliases":["ETER100","TQB2450-III-07","A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer","A Randomized, Positive Parallel Controlled, Multicenter Phase III Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer"],"brief_title":"A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Advanced Renal Cancer"],"display_condition":"first-line advanced renal cell carcinoma","display_interventions":[["benmelstobart","anlotinib"]],"enrollment":{"count":528,"type":"ACTUAL"},"interventions":[{"name":"TQB2450","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Anlotinib","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Sunitinib","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT04523272","official_title":"A Randomized, Positive Parallel Controlled, Multicenter Phase III Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer","overall_status":"UNKNOWN","phase":["PHASE3"],"primary_completion_date":{"date":"2025-06","type":"ESTIMATED"},"primary_endpoints":[{"description":"PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause, based on IRC.","measure":"Progression free survival (PFS) evaluated by Independent Review Committee(IRC)","timeFrame":"up to 60 weeks"}],"registered_date":{"date":"2020-08-21","type":"ACTUAL"},"registry_last_updated":"2024-10-15","registry_url":"https://clinicaltrials.gov/study/NCT04523272","short_name":"ETER100","short_name_basis":"canonical_name","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","start_date":{"date":"2020-08-25","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"TQB2450-III-07","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}